Skip to content
Dosage GuideResearch Reference

Actovegin Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Actovegin. All information is for educational purposes only.

Quick Answer

Actovegin dosage varies by administration route and condition. IV dosages range from 800-2,000 mg daily for acute neurological conditions. Oral dosages are typically 600-1,800 mg daily. Intramuscular injections range from 200-400 mg daily. Treatment courses usually last 4-6 weeks, adjusting based on response and indication.

→ Actovegin Benefits→ Actovegin Side Effects→ Full Actovegin Profile
Table of Contents

Standard Dosage Range

Research dosing range: 800–2,000 mg IV; 600–1,800 mg oral; 200–400 mg IM

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Post-Stroke Cognitive Impairment

2,000 mg1× daily (IV)
Duration

20 days, then 1,200 mg oral daily for 6 months

Based on the ARTEMIDA trial protocol. Initiate IV infusion soon after stroke event.

Diabetic Polyneuropathy

800 mg1× daily (IV)
Duration

3 weeks, then 600 mg oral daily for 4-6 weeks

IV infusion followed by oral maintenance. Monitor nerve conduction velocity and neuropathic symptoms.

Vascular Dementia

600 mg3× daily (oral)
Duration

4–6 weeks

Administer before meals. Assess cognitive function using standardized tests (e.g., MMSE).

Wound Healing

400 mg1× daily (IM)
Duration

2-4 weeks

Limited to 5mL per injection site. Assess the rate of wound closure.

Timing & Frequency

For IV administration, infuse slowly over 2-3 hours. Oral doses are taken before meals to enhance absorption. Time of day is not critical, but consistency is advised.

Cycle Guidance

Treatment courses typically last 4-6 weeks, although longer durations may be used for chronic conditions like vascular dementia or diabetic neuropathy. Monitor for adverse effects and clinical response. Consider intermittent cycles with breaks for long-term use.

Reconstitution Reference

Quick reference for reconstituting Actovegin. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeAvailable in various sizes (40mg/mL, 200mg/5mL)
BAC Water VolumeNot applicable, already in solution for injection
Concentration & Draw40 mg/mL (typical)
StorageStore ampules at room temperature, protect from light. Do not refrigerate.
StabilityRefer to manufacturer specifications. Discard after single use.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical IV dosage for stroke recovery?
The ARTEMIDA trial used 2,000 mg IV daily for 20 days. This is considered a standard dose for acute neurological conditions following stroke. Consult with a neurologist for specific recommendations.
How should oral Actovegin be taken?
Oral tablets should be taken before meals to enhance absorption. The typical dosage is 200 mg three times daily, but this may vary depending on the indication and individual response.
Can Actovegin be administered intramuscularly?
Yes, Actovegin can be administered intramuscularly, typically at a dose of 200-400 mg daily. Injections are limited to 5 mL per injection site to minimize discomfort.
How long does a typical treatment course last?
Treatment courses usually last 4-6 weeks. Longer durations may be appropriate for chronic conditions, but monitoring for adverse effects and clinical response is crucial.
What should I do if I miss a dose?
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at once.

References

  1. 1
    Actovegin in the treatment of patients with post-stroke cognitive impairment: ARTEMIDA (A Randomized Trial of Efficacy, 12 Months International Double-blind Actovegin)(2017)PubMed ↗
  2. 2
    Efficacy and safety of Actovegin in the management of diabetic polyneuropathy: a randomized controlled trial(2009)PubMed ↗
  3. 3
    The effect of actovegin on the structural and functional state of the brain in patients with chronic cerebral ischemia(2013)PubMed ↗

Last updated: 2026-02-19